An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®). "ROSE"


Phase N/A Results N/A

Summary of Purpose

This study aims to evaluate the use of rivaroxaban and its short term safety when used by patients for the new indications of prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. Any adult patient started by their care team on rivaroxaban or an alternative...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 26 January 2018.

1 May 2013 29 May 2013 1 Jan 2016 1 Sep 2017 1 Jan 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample